Prostatype Genomics Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
PROGEN
- Share Price
-
$0.77
- (As of Friday Closing)
Prostatype Genomics General Information
Description
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Contact Information
Website
www.prostatypegenomics.comCorporate Office
- Industrivägen 19
- 171 48 Solna
- Sweden
Corporate Office
- Industrivägen 19
- 171 48 Solna
- Sweden
Prostatype Genomics Stock Performance
As of 06-Dec-2024, Prostatype Genomics’s stock price is $0.77. Its current market cap is $3.96M.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.77 | $0.75 | $0.49 - $11.26 | $3.96M | 17K | -$8.82 |
Prostatype Genomics Financials Summary
As of 30-Jun-2024, Prostatype Genomics has a trailing 12-month revenue of $96.2K.
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 3,414 | 745 | 2,973 | 12,047 |
Revenue | 96 | 128 | 67 | 1 |
EBITDA | (3,413) | (3,577) | (2,640) | (1,800) |
Net Income | (3,809) | (3,898) | (2,867) | (1,820) |
Total Assets | 3,034 | 4,925 | 2,967 | 4,442 |
Total Debt | 0 | 1,167 | 83 | 140 |
Prostatype Genomics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Prostatype Genomics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Prostatype Genomics Patents
Prostatype Genomics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
ES-2689547-T3 | Marker genes for prostate cancer classification | Active | 24-Oct-2011 | ||
US-9790555-B2 | Marker genes for prostate cancer classification | Active | 24-Oct-2011 | ||
US-20140243433-A1 | Marker genes for prostate cancer classification | Active | 24-Oct-2011 | ||
CA-2852020-A1 | Marker genes for prostate cancer classification | Active | 24-Oct-2011 | ||
CA-2852020-C | Marker genes for prostate cancer classification | Active | 24-Oct-2011 | C12Q1/6886 |
Prostatype Genomics Signals
Prostatype Genomics FAQs
-
When was Prostatype Genomics founded?
Prostatype Genomics was founded in 2007.
-
Where is Prostatype Genomics headquartered?
Prostatype Genomics is headquartered in Solna, Sweden.
-
What is the size of Prostatype Genomics?
Prostatype Genomics has 7 total employees.
-
What industry is Prostatype Genomics in?
Prostatype Genomics’s primary industry is Diagnostic Equipment.
-
Is Prostatype Genomics a private or public company?
Prostatype Genomics is a Public company.
-
What is Prostatype Genomics’s stock symbol?
The ticker symbol for Prostatype Genomics is PROGEN.
-
What is the current stock price of Prostatype Genomics?
As of 06-Dec-2024 the stock price of Prostatype Genomics is $0.77.
-
What is the current market cap of Prostatype Genomics?
The current market capitalization of Prostatype Genomics is $3.96M.
-
What is Prostatype Genomics’s current revenue?
The trailing twelve month revenue for Prostatype Genomics is $96.2K.
-
What is Prostatype Genomics’s annual earnings per share (EPS)?
Prostatype Genomics’s EPS for 12 months was -$8.82.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »